Across TCGA pan-cancer cohorts, IGHV3-49 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGHV3-49 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IGHV3-49 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-49 expression acts as an unfavorable survival marker.

LUSC, BRCA, and LUAD are the cancer types where IGHV3-49 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.181	0.762	.027	21	view →
BRCA	DFS	Median	All	0.130	0.526	.018	8	view →
LUAD	OS	Median	All	0.188	0.670	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGHV3-49 tumor-vs-normal RNA expression · all IGHV3-49 data types